Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
Apple Eyes Chinese Memory Chips as AI Shortage Pressures iPhone Supply Chain 
South Korea Alleges Google Abused Android App Store Dominance, Eyes Major Fine 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Trump Reports $1.4 Billion in Crypto Income as Digital Assets Become Top Wealth Source 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
Kawasaki Heavy Shares Slide on Report of ¥200 Billion Capital Raise Plan 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Orion Group purchased a controlling stake in LegoChem Biosciences, a South Korean research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines. The confectionery company is acquiring a 25.7% stake worth KRW550 billion or around $418 million.
With the size of its acquisition, the Orion Group has now become the largest shareholder of LegoChem Biosciences. The firm made the deal as it seeks to broaden its business and enter into new drug development business beyond antibody-drug conjugate platform technology, as per the Korea Joongang Daily.
What is Included in the Agreement
Pan Orion Corporation, the Hong Kong-headquartered subsidiary of the Orion Group, led the acquisition deal. Based on the reports, the agreement includes a combination of share purchases and rights offerings.
Moreover, it was stated in the electronic disclosure of the Financial Supervisory Service that Orion will buy 7.96 million units of new stakes at KRW59,000 per share. In addition, it will also purchase 1.4 million existing shares at the base rate of 56,186 per share. Orion is scheduled to settle the payment for the acquisition on March 29.
Orion's Venture Into Biotech Business
The Korea Economic Daily reported that this buyout deal not only marks the Orion Group's deeper venture into the biotech industry but is also expected to help the company in achieving its goal of giving a boost to LegoChem Biosciences by providing the needed financial push for clinical development and encouraging new technology research.
Once the deal is completed, Orion will be the largest shareholder in LegoChem Biosciences. Currently, the company's chief executive officer, Kim Yong Zu, holds the biggest share, and after the acquisition, he will still retain some of his shares and keep his CEO position. LegoChem is also set to become one of the confectionery giant's affiliates.
Photo by: Orion Website
